

BOX AFO



1292
97.D
JAB 828

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Cornelius G. M. Janssen et al.

Serial No.: 07/932,142

Art Unit: 1202

Filed : August 19, 1992

Examiner: M. Berch

For : NOVEL 3-PIPERIDINYL-1,2-BENZISOXAZOLES

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

RECEIVED

APR 15 1993

GROUP 1200

RECEIVED
INT'L LAW DIVISION

MAR 5 1 1993

— TO FILE REFER TO CS

Your Petitioner, JANSSEN PHARMACEUTICA N.V., a corporation of Belgium, having an address at Turnhoutseweg 30, B-2340 Beerse, Belgium, represents that it is the Assignee of the entire right, title and interest in and to the subject matter disclosed in the above-captioned patent application by virtue of its being a divisional of U.S. Patent Application Serial No. 07/422,847, filed October 17, 1989, which was assigned to JANSSEN PHARMACEUTICA N.V., the assignment being recorded in the United States Patent and Trademark Office on November 13, 1989, on Reel 5171, Frame 0567.

Your Petitioner, JANSSEN PHARMACEUTICA N.V., hereby disclaims, under the provisions of 35 U.S.C. 253, the terminal part of any patent granted on application Serial No. 07/932,142 which would extend beyond the expiration date of United States Patent No. 5,158,952, also assigned to JANSSEN PHARMACEUTICA N.V. (assignment recorded on November 13, 1989, on Reel 5171, Frame

0567), and hereby agrees that any patent so granted on application Serial No. 07/932,142 shall be enforceable only for and during such period that the legal title of said patent shall be the same as the legal title to United States Patent No. 5,158,952, this agreement to run with any patent granted on application Serial No. 07/932,142 and to be binding upon the grantee, its successors or assigns.

The undersigned has reviewed the assignments referred to above and it is certified that, to the best of the undersigned's knowledge and belief, title to the patent and patent application referred to herein is in JANSSEN PHARMACEUTICA N.V.

Signed at Beerse, Belgium, this 26th day of March, 1993.

Respectfully submitted,

JANSSEN PHARMACEUTICA N.V.

By: Wantel
Dirk Wantel
Head Patent Department, Proxy Holder

Charles J. Metz
Attorney for Applicants
Reg. # 20,359
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

(908) 524-2814